Lowest Price Guaranteed From USD 4,899
The immune checkpoint inhibitors market is estimated to be worth $12 billion in 2030 and is expected to grow at CAGR of 15% during the forecast period. Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients’ quality of life. There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb’s Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1 / PD-L1 immune checkpoint inhibitors drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics.
Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade / co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing / treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial market growth during the forecast period.
Examples of key companies engaged in immune checkpoint inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Novartis and Trillium Therapeutics. This market report includes an easily searchable excel database of all the companies developing immune checkpoint inhibitors, worldwide.
Several recent developments have taken place in the field of immune checkpoint inhibitors market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Immune Checkpoint Inhibitors Market, 2020-2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the immune checkpoint inhibitors market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in immune checkpoint inhibitors market.
In addition to other elements, the market research report includes:
The key objective of immune checkpoint inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for immune checkpoint inhibitors market during the forecast period. Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the forecast period 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus / lupus nephritis) [B] key immune checkpoint targets (B7-H3, CD38, CD40, CD47 and ICOS [C] mechanisms of action (inhibitory and costimulatory), [D] therapeutic modalities used (antibody fragment, monoclonal antibody and small molecule), [E] type of therapy (monotherapy, combination therapy and both), [F] route of administration (intravenous, subcutaneous and intracerebroventricular) and [G] key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in immune checkpoint inhibitors market. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market report are in USD, unless otherwise specified.